Oral Small Molecule Therapeutics
•249 stocks
•
Total Market Cap: Loading...
Market Cap Distribution
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (249)
%
| Company | Market Cap | Price |
|---|---|---|
|
Oral small-molecule GLP-1 therapies (Orforglipron, Muvalaplin) are major Lilly products.
|
$789.93B |
$833.49
-2.86%
|
|
Oral small-molecule therapeutics in the pipeline (e.g., Icotrokinra) expanding administration options.
|
$458.89B |
$190.72
-0.67%
|
|
Rinvoq and Tavapadon (Parkinson's) are oral small-molecule therapeutics, a major AbbVie product category.
|
$431.71B |
$236.56
-1.80%
|
|
The company is pursuing oral small molecule therapeutics (e.g., AZD0780 PCSK9 inhibitor, Baxdrostat, oral GLP-1) as a growth engine.
|
$262.04B |
$84.53
-1.28%
|
|
Oral Small Molecule Therapeutics encompass Kisqali and Remibrutinib, a core drug category.
|
$252.00B |
$130.00
|
|
Januvia/Janumet are major oral small-molecule therapeutics in Merck's portfolio.
|
$200.78B |
$79.96
-0.16%
|
|
Otezla (apremilast) represents Amgen's portfolio of oral small molecule therapeutics.
|
$156.00B |
$290.13
-2.04%
|
|
Biktarvy and Descovy are oral small-molecule antiretrovirals, fitting the Oral Small Molecule Therapeutics category.
|
$145.76B |
$117.18
-0.40%
|
|
Rilzabrutinib is an oral small‑molecule therapeutic (BTK inhibitor), placing Sanofi in the Oral Small Molecule Therapeutics category.
|
$120.19B |
$98.46
|
|
Vertex's ALYFTREK (CFTR modulator) and TRIKAFTA are oral small-molecule therapeutics for cystic fibrosis, representing a core product category.
|
$104.72B |
$407.79
-1.34%
|
|
Milvexian and Iberdomide are oral small-molecule therapeutics, aligning with the Oral Small Molecule Therapeutics category.
|
$89.46B |
$43.96
-1.83%
|
|
Zoetis sells oral small-molecule therapeutics (e.g., Apoquel) for companion animal dermatology/immunology.
|
$62.82B |
$141.11
-1.59%
|
|
Zasocitinib is an oral small-molecule TYK2 inhibitor, placing Takeda in the oral small-molecule therapeutics category.
|
$43.58B |
$27.33
-2.62%
|
|
BeOne's pipeline includes multiple oral small-molecule oncology agents (BTK inhibitors, BCL-2 inhibitors, CDK4 inhibitors).
|
$34.59B |
$320.10
-3.00%
|
|
Brensocatib is an oral small-molecule therapeutic, aligning with the Oral Small Molecule Therapeutics tag.
|
$29.57B |
$162.33
-1.08%
|
|
AUSTEDO and pipeline assets include oral small-molecule therapeutics.
|
$22.95B |
$20.01
+0.05%
|
|
Orenitram is an oral small-molecule prostacyclin receptor agonist; Ralinepag is a prominent oral small-molecule prostacyclin receptor agonist in late-stage development.
|
$19.85B |
$440.00
-1.27%
|
|
Incyte's core business includes small-molecule therapeutics (e.g., oral JAK inhibitors) and an actively developed pipeline of other oral NCEs.
|
$16.22B |
$83.80
-1.42%
|
|
INGREZZA and the Neurocrine CNS portfolio are driven by oral small-molecule therapeutics, including a broad pipeline of additional small-molecule CNS agents.
|
$14.51B |
$146.95
+0.38%
|
|
Weight-loss offering with oral small molecule therapeutics or related drug-delivery products through the platform.
|
$12.08B |
$53.95
-7.45%
|
|
The company has a significant small-molecule business (e.g., lenalidomide generic) with ongoing US launches and price erosion risks.
|
$11.96B |
$14.34
+1.63%
|
|
Viatris' pipeline includes fast-acting meloxicam and other oral small-molecule therapeutics (e.g., sotagliflozin licensing).
|
$11.17B |
$9.52
-0.42%
|
|
Brepocitinib is a dual TYK2/JAK1 inhibitor delivered orally, classed as an Oral Small Molecule Therapeutics program.
|
$10.90B |
$16.04
-0.50%
|
|
Attruby (acoromidis) and other pipeline assets (encaleret, infigratinib, BBP-418) are primarily oral small-molecule therapeutics.
|
$10.54B |
$55.49
+1.20%
|
|
Zanzalintinib and cabozantinib are oral small-molecule therapeutics, a core product category for Exelixis.
|
$10.40B |
$38.15
-1.34%
|
|
BMN-349 is described as an oral small-molecule therapeutic in BioMarin's pipeline.
|
$10.03B |
$52.32
-3.40%
|
|
Rezdiffra is an oral, liver-directed small-molecule therapeutic, which is Madrigal's core product.
|
$9.54B |
$429.60
+0.21%
|
|
If the formulations are designed for oral administration, they align with the Oral Small Molecule Therapeutics category as a major therapeutic modality.
|
$8.31B |
$16.81
-8.54%
|
|
AYVAKIT and the pipeline assets are oral small-molecule therapeutics targeting KIT, making 'Oral Small Molecule Therapeutics' a core product category.
|
$8.27B |
$129.46
|
|
Xywav, Epidiolex, Zepzelca and other products are oral small molecule or biologic therapies.
|
$7.99B |
$129.59
-0.16%
|
|
Corcept's portfolio centers on oral small-molecule therapies (Korlym and relacorilant) targeting cortisol pathways.
|
$7.84B |
$73.96
-15.51%
|
|
Aficamten, omecamtiv mecarbil, ulacamten, and CK-089 are described as small-molecule therapeutics, indicating the Oral Small Molecule Therapeutics theme.
|
$7.17B |
$60.04
-0.38%
|
|
Bivamelagon is an oral small molecule MC4R agonist in Rhythm's pipeline, fitting the Oral Small Molecule Therapeutics category.
|
$6.41B |
$100.82
+1.04%
|
|
Auvelity, Sunosi, Symbravo and pipeline candidates are oral small-molecule therapeutics.
|
$5.99B |
$121.71
-0.66%
|
|
Abivax's lead drug obefazimod is an oral small-molecule therapeutic targeting inflammatory bowel disease.
|
$5.90B |
$93.77
+0.06%
|
|
Nuvalent develops oral small molecule therapeutics (kinase inhibitors) for cancer, fitting the Orals Small Molecule Therapeutics category.
|
$5.84B |
$81.39
+4.24%
|
|
Sephience (PKU) and other PTC oral small molecule programs (vatiquinone, PTC518) are directly developed and commercialized as oral small molecule therapeutics.
|
$5.25B |
$66.23
+0.23%
|
|
Lead and other products are oral small-molecule therapeutics (e.g., LYBALVI) and the orexin program includes an oral candidate (alixorexton).
|
$5.15B |
$31.21
-0.54%
|
|
The company develops oral, nonpeptide small molecule therapeutics (e.g., paltusotine) for endocrine GPCR targets.
|
$4.08B |
$42.32
-2.74%
|
|
Oral small molecule therapeutics: Kymera aims to deliver biologics-like efficacy with oral dosing, representing a major product class.
|
$4.00B |
$56.00
+1.49%
|
|
VK2809 is a liver-targeted small-molecule TRβ agonist with oral administration, aligning with the Oral Small Molecule Therapeutics category.
|
$3.77B |
$33.56
-6.13%
|
|
Lead products LIVMARLI and Volixibat are oral small-molecule therapeutics (IBAT inhibitors) addressing cholestatic diseases.
|
$3.64B |
$73.57
-0.65%
|
|
NUPLAZID and DAYBUE include oral/deliverable small-molecule/peptide therapies and related mid- to late-stage programs, fitting the oral small molecule therapeutics category for major drug products.
|
$3.52B |
$21.05
-0.94%
|
|
Oral Small Molecule Therapeutics: SpringWorks' approved assets OGSIVEO and GOMEKLI are oral, small-molecule targeted therapies forming the core revenue streams.
|
$3.52B |
$46.99
|
|
KarXT and other oral small molecules represent a major revenue-driving drug category.
|
$3.43B |
$31.62
+0.86%
|
|
Obicetrapib is an oral small-molecule therapeutic candidate developed by NewAmsterdam Pharma, representing the core product category.
|
$3.42B |
$37.05
+10.86%
|
|
SUBOXONE Film and other buprenorphine therapies include oral small-molecule therapeutics, corresponding to Oral Small Molecule Therapeutics.
|
$3.28B |
$23.78
-1.53%
|
|
Soleno's VYKAT XR is an oral small-molecule therapeutic targeted at hyperphagia in Prader-Willi Syndrome.
|
$3.27B |
$62.72
-1.74%
|
|
HUTCHMED directly develops and sells oral, small-molecule targeted therapeutics across oncology and immunology indications.
|
$3.15B |
$3.66
|
|
Xenon’s portfolio centers on oral small‑molecule CNS therapeutics (Kv7 opener XEN1101 and related programs) with epilepsy and neuropsychiatric expansion.
|
$3.04B |
$39.64
-4.34%
|
|
ORX750 is an orally administered orexin receptor agonist, i.e., an oral small molecule therapeutic.
|
$2.98B |
$22.31
-2.75%
|
|
TP-05 is an oral systemic lotilaner candidate, representing the oral small-molecule therapeutic category in development.
|
$2.95B |
$70.14
-0.09%
|
|
The company’s lead assets are oral small-molecule cancer therapies (e.g., lisaftoclax is an oral Bcl-2 inhibitor; olverembatinib is an oral BCR-ABL inhibitor).
|
$2.75B |
$34.94
-5.05%
|
|
Lorundrostat is an orally administered, small-molecule therapeutic, aligning Mineralys with the 'Oral Small Molecule Therapeutics' category.
|
$2.75B |
$42.16
+6.98%
|
|
Major product category for the company's oral small-molecule therapeutics (e.g., Qelbree, GOCOVRI, ONAPGO, SPN-817, SPN-820, SPN-443).
|
$2.74B |
$49.00
-0.79%
|
|
Galafold is an oral small-molecule therapeutic; the Pompe therapy includes an oral stabilizer component, making the major product category oral small-molecule therapeutics.
|
$2.56B |
$8.30
|
|
Company develops oral small-molecule therapeutics (bitopertin and DISC pipeline), a major product category in pharma.
|
$2.42B |
$69.90
-0.87%
|
|
Agios' lead product mitapivat and pipeline tebapivat are oral small‑molecule therapeutics for rare hematologic diseases.
|
$2.35B |
$40.61
-4.47%
|
|
FIRDAPSE, AGAMREE, and FYCOMPA are oral small-molecule therapies, mapping to the Oral Small Molecule Therapeutics category.
|
$2.33B |
$19.13
-2.60%
|
|
Tinlarebant is a lead oral small-molecule therapeutic (LBS-008) targeting retinal diseases.
|
$2.31B |
$79.28
+1.03%
|
|
IDEAYA develops small molecule therapies (e.g., darovasertib, IDE397) which fit the Oral Small Molecule Therapeutics category.
|
$2.30B |
$26.24
-2.42%
|
|
GLPG3667 is an oral TYK2 inhibitor, representing a non-cell-therapy pipeline with small-molecule therapeutics.
|
$2.25B |
$34.10
+0.86%
|
|
Xifaxan and related oral small-molecule therapeutics are a major product line.
|
$2.24B |
$6.05
-4.87%
|
|
Sparsentan is an oral small molecule therapeutic, aligning with the 'Oral Small Molecule Therapeutics' investable theme.
|
$2.21B |
$24.85
+2.10%
|
|
Oral Small Molecule Therapeutics captures Prucalopride launch and related generics activity within ANI's product mix.
|
$1.99B |
$90.17
-1.51%
|
|
Lead asset bezuclastinib is an oral small-molecule tyrosine kinase inhibitor targeting KIT D816V, aligning with the Oral Small Molecule Therapeutics category.
|
$1.85B |
$16.27
|
|
Covers oral small-molecule therapeutics including troriluzole and BHV-7000 across neuroscience, OCD, and pain indications.
|
$1.61B |
$15.80
-9.97%
|
|
Core product category: oral small molecule therapeutics.
|
$1.61B |
$28.00
+10.54%
|
|
Edgewise's core offerings are orally administered small-molecule therapeutics (sevasemten, EDG-7500).
|
$1.59B |
$15.11
-5.92%
|
|
Casdatifan and other Arcus assets (CD73 inhibitor quemliclustat, A2A/A2B antagonist etrumadenant) are oral small-molecule therapeutics.
|
$1.55B |
$14.60
-4.20%
|
|
LUPKYNIS is an oral small-molecule therapeutic, aligning with the 'Oral Small Molecule Therapeutics' category.
|
$1.53B |
$11.35
+0.44%
|
|
Harmony's pipeline centers on oral small molecule CNS therapies (narcolepsy/EDS, rare neuropsychiatric indications) and WAKIX is an oral small molecule; multiple assets in development follow this format.
|
$1.52B |
$26.54
-1.19%
|
|
ORLADEYO is BioCryst's flagship oral small-molecule therapeutic for hereditary angioedema, forming the core product and revenue driver.
|
$1.51B |
$7.22
-0.48%
|
|
Avadel directly markets LUMRYZ, an oral small-molecule therapeutic for narcolepsy.
|
$1.51B |
$15.49
-0.61%
|
|
Revuforj is an oral small-molecule therapeutic (menin inhibitor), aligning with 'Oral Small Molecule Therapeutics'.
|
$1.38B |
$16.06
-1.35%
|
|
Company develops small-molecule oral CFTR modulators (SION-719, SION-451) targeting CF; a core oral small molecule therapeutics product category.
|
$1.32B |
$29.93
-0.28%
|
|
IBTROZI, Safusidenib, and NUV-868 are oral small molecule therapeutics, aligning with this tag.
|
$1.27B |
$3.74
-1.84%
|
|
AMX0035 is an oral fixed-dose small-molecule therapeutic, fitting the Oral Small Molecule Therapeutics category.
|
$1.27B |
$14.26
-1.11%
|
|
Maze develops oral small molecule therapeutics (MZE829, MZE782) for CVRM/renal diseases, which fits the 'Oral Small Molecule Therapeutics' category.
|
$1.20B |
$27.43
-4.62%
|
|
OPKO's OPK-88006 program includes an oral form (Entera Bio collaboration) of a dual GLP-1/glucagon analog, categorized as Oral Small Molecule Therapeutics.
|
$1.20B |
$1.51
-3.21%
|
|
Deucrictibant is an oral small-molecule therapeutic intended for on-demand and prophylactic treatment of hereditary and acquired angioedema.
|
$1.19B |
$21.98
-3.21%
|
|
Ardelyx directly develops and commercializes oral small-molecule therapeutics (tenapanor) for IBS-C (IBSRELA) and hyperphosphatemia (XPHOZAH).
|
$1.18B |
$4.94
-2.18%
|
|
RLY-2608 is described as an oral small molecule therapeutic, aligning with Oral Small Molecule Therapeutics.
|
$1.11B |
$6.50
-5.80%
|
|
Direct product category: Haduvio is an oral small molecule therapeutic (nalbuphine ER) targeting chronic cough.
|
$1.11B |
$8.95
+2.17%
|
|
Direct products Jornay PM, Belbuca, Xtampza ER, and Nucynta ER/IR are small‑molecule prescription therapeutics; tag corresponds to the major product category these Rx therapies belong to (Oral Small Molecule Therapeutics).
|
$1.11B |
$34.22
-0.55%
|
|
XACDURO and zoliflodacin are small-molecule therapeutics (including oral candidates), representing major product assets Innoviva directly markets/develops.
|
$1.09B |
$17.35
-0.91%
|
|
VLS-01 and related formulations are small-molecule therapeutics delivered via buccal film (oral administration).
|
$1.05B |
$5.23
+1.16%
|
|
Septerna's core focus is discovery and development of oral small-molecule therapeutics targeting GPCRs (platform-enabled drug discovery).
|
$1.03B |
$23.07
+5.20%
|
|
Lead assets are oral, small-molecule therapeutics (ROS1 NSCLC; IDH1 glioma), aligning with Oral Small Molecule Therapeutics.
|
$1.02B |
$3.20
+5.26%
|
|
ORIC-114 is an orally bioavailable small-molecule inhibitor, and the pipeline centers on oral small-molecule cancer therapeutics, supporting the 'Oral Small Molecule Therapeutics' category.
|
$972.48M |
$13.68
-2.84%
|
|
Joenja (leniolisib) and related assets are oral small-molecule therapeutics, a major product category for the company.
|
$968.01M |
$14.27
-3.58%
|
|
Lead asset RAP-219 is a small-molecule therapeutic with oral administration, aligning with the Oral Small Molecule Therapeutics category.
|
$967.19M |
$26.50
-1.08%
|
|
The company develops orally administered small molecule therapeutics (ELVN-001/ELVN-002), aligning with the Oral Small Molecule Therapeutics category.
|
$962.25M |
$19.61
-2.34%
|
|
MM120 is an oral small-molecule therapeutic (psychedelic/derivative), aligning with Oral Small Molecule Therapeutics.
|
$892.28M |
$11.81
-5.75%
|
|
Praxis' Cerebrum platform develops orally administered small-molecule therapeutics (e.g., ulixacaltamide, vormatrigine, relutrigine).
|
$859.98M |
$47.67
-1.37%
|
|
Ziftomenib and KO-2806/tipifarnib are oral small molecule therapeutics in oncology, directly matching the Oral Small Molecule Therapeutics category.
|
$852.76M |
$9.85
-4.09%
|
|
AB-101 is an oral small-molecule PD-L1 inhibitor; Arbutus directly develops this therapeutic candidate.
|
$831.23M |
$4.34
-1.14%
|
|
VOQUEZNA (vonoprazan) is an oral small molecule therapeutic (P-CAB) marketed as the core product for GERD and H. pylori therapy.
|
$825.20M |
$11.82
+0.17%
|
|
Developer of an oral small molecule therapeutic (ANAVEX 2-73), aligning with Oral Small Molecule Therapeutics.
|
$791.40M |
$9.27
-1.80%
|
|
Olema develops oral small-molecule therapeutics, including palazestrant (OP-1250) and OP-3136.
|
$759.48M |
$11.10
-0.36%
|
Showing page 1 of 3 (249 total stocks)
Loading industry metrics...
Loading comparison data...
